MFG
CHRS icon

Merit Financial Group’s Coherus Oncology CHRS Stock Holding History

Merit Financial Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Buy
10,935
+327
+3% +$534 ﹤0.01% 2341
2026
Q1 		$17.9K Buy
+10,608
New +$18.8K ﹤0.01% 2101

Other funds holding CHRS

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Merit Financial Group's CHRS Position: Q2 2026 in Review

Merit Financial Group increased its Coherus Oncology (CHRS) stake by 3.1% in Q2 2026, buying an estimated $534 and bringing the position to 10,935 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Merit Financial Group first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $17.9K in Q1 2026. 11 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Merit Financial Group held 10,935 shares of Coherus Oncology worth $15.3K as of Q2 2026.
  • Merit Financial Group bought 327 Coherus Oncology shares in Q2 2026, an estimated $534.
  • Coherus Oncology made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2341 holding.
  • Merit Financial Group first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Merit Financial Group's Coherus Oncology position peaked at $17.9K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.